title: [RANKL inhibition in bone metastases].
authors.affiliation: wada.teiji.fv@daiichisankyo.co.jp
authors.forename: Teiji
authors.initials: T
authors.lastname: Wada
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary*; D001862:Bone Resorption / Q000517:prevention & control; D001842:Bone and Bones / Q000378:metabolism; D000069448:Denosumab; D004195:Disease Models, Animal; D015195:Drug Design; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy; D051379:Mice; D058990:Molecular Targeted Therapy; D053244:Osteoprotegerin / Q000502:physiology; D053245:RANK Ligand / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000502:physiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505686:TNFRSF11A protein, human; D000069448:Denosumab